Paclitaxel and cisplatin as salvage treatment in patients with non-seminomatous germ cell tumour who failed to achieve a complete remission on induction chemotherapy

Tjulandin, Sergei; Титов, Д.А.; Бредер, В. В.; Sidorova, N.J.; Popov, A. Yu.; Купчан, Д. З.; Garin, A.

doi:10.1016/s0936-6555(98)80080-0

Cited by 3 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients in this trial were limited to one prior cisplatin-containing regimen. A trial reported in 1998 demonstrated that the combination of cisplatin and paclitaxel 36 achieved an overall response rate of 25% with 1 CR (6%) in 16 patients who had not achieved remission to first-line therapy. The addition of ifosfamide to cisplatin and paclitaxel 37 produced a CR rate of 63% in 16 patients with primary testicular neoplasms who had relapsed from initial therapy.…”

Section: Salvage Therapymentioning

confidence: 99%

Chemotherapy of Testis Cancer

Benedetto

1999

Cancer Control

View full text Add to dashboard Cite

Prior to the use of cisplatin, durable complete remissions of metastatic testis cancer were rare. In 1977, a treatment program including a chemotherapy program of cisplatin, vinblastine, and bleomycin (PVB) led to high response rates and acceptable toxicities in patients with disseminated testis cancer. Since then, the BEP (bleomycin, etoposide, and cisplatin) regimen has been established as standard therapy for good-and poor-risk disease and ifosfamide-based regimens or high-dose chemotherapy with stem cell rescue as salvage therapy. Methods: The results of those prospective, randomized clinical trials that have markedly improved the outlook of patients with this type of cancer have been reviewed. Results: Categories of risk have been defined. Standard therapy for both good-risk and poor-risk disease remains BEP therapy. High-dose chemotherapy with autologous bone marrow or peripheral stem cell rescue transplantation is being investigated to overcome chemotherapy resistance. Conclusions: While the present state of the art for treating metastatic testicular cancer is promising, approximately one third of patients with "poor-risk" disease will not achieve a remission. Trials of new agents and approaches are needed to increase patient survival. Current chemotherapy for patients with metastatic testicular cancer has resulted in high cure rates with acceptable long-term toxicity.

show abstract

Section: Salvage Therapymentioning

confidence: 99%